Flash Finance

Krebs Biochemicals and Industries LimitedKREBSBIOCorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹60.19
MCap ₹130 Cr
Krebs Biochemicals and Industries Limited — Stock analysis & AI research Krebs Biochemicals and Industries Limited — Seasonality — best & worst months Krebs Biochemicals and Industries Limited — Technical setup — score, trend, support & resistance Krebs Biochemicals and Industries Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹7 Cr
Sales · Jun 2026
+27.4% YoY
₹1 Cr
Operating Profit · Jun 2026
+139.6% YoY
11.8%
OPM % · Jun 2026
+131.0% YoY
₹-2 Cr
Net Profit · Jun 2026
+53.3% YoY
₹-1.15
EPS · Jun 2026
+53.4% YoY

📝 Krebs Biochemicals and Industries Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Krebs Biochemicals and Industries Limited reported revenue of ₹7 crore for the quarter ended June 2026 (Q1 FY27), up 27.4% from ₹5 crore in the same quarter last year, and up 2.6% sequentially over the March 2026 quarter.

The company reported a net loss of ₹2 crore, against a net loss of ₹5 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-1.15.

Operating profit stood at ₹1 crore — an operating margin (OPM) of 11.8%, compared with -38.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Krebs Biochemicals and Industries Limited posted revenue of ₹24 crore, a decline of 45.2% over FY25, with a net loss of ₹17 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹25 crore with a net loss of ₹14 crore.

Valuation snapshot

At the current price of ₹60.19, KREBSBIO has a market capitalisation of ₹130 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the 10th-largest of the 11 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 72.74%, foreign institutional investors (FIIs) 0.50%, public shareholders 26.76% of Krebs Biochemicals and Industries Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹130 Cr
Current Price ?
₹60.2
P/E ?
N/A
Industry P/E ?
32.10
P/B ?
-0.80
P/S ?
5.14
P/FCF ?
-25.95
Enterprise Value ?
₹355 Cr
EV/EBITDA ?
-139.89
PEG ?
N/A
Earnings Yield ?
-2.5%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹25 Cr
OPM ?
-10.0%
Profit after tax (TTM) ?
₹-14 Cr
EPS (TTM) ?
₹-6.54
ROCE ?
-15.0%
ROE ?
8.7%
ROA ?
-8.6%
Growth
Sales — latest qtr ?
₹7 Cr
PAT — latest qtr ?
₹-2 Cr
YoY qtr sales growth ?
27.4%
YoY qtr profit growth ?
53.3%
Sales growth (3y) ?
-23%
Sales growth (5y) ?
-15%
Profit growth (3y) ?
10%
Profit growth (5y) ?
7%
Financial Health
Debt ?
₹225 Cr
Debt to Equity ?
-1.39
Interest Coverage ?
-1.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
72.74%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
12.1%
Return 6 months ?
-3.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1111151312131311654777 +27.4% +2.6%
Operating Profit -5-3-1-2-3-2-3-5-5-2-30-11 +139.6% +195.3%
Other Income 00000000000020 +1237.6% -92.2%
Interest 11111112222222 +14.0% -1.5%
Depreciation 12222222222222 -0.7% +1.4%
Profit Before Tax -7-5-4-5-6-5-6-8-8-5-6-3-2-2 +53.3% -6.2%
Net Profit -7-5-4-5-6-5-6-8-8-5-6-3-2-2 +53.3% -6.2%
EPS -3.07-2.47-1.66-2.31-2.72-2.40-2.67-3.59-3.83-2.47-2.85-1.45-1.09-1.15 +53.4% -5.5%
OPM % -40.3% -24.8% -6.0% -16.1% -26.0% -17.0% -21.1% -41.1% -88.6% -38.1% -67.0% 4.1% -12.7% 11.8% +131.0% +192.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹43 Cr ₹24 Cr ₹25 Cr -45.2%
Operating Profit ₹-15 Cr ₹-5 Cr ₹-3 Cr +63.7%
OPM % -34.70% -22.97% -10.05% +33.8%
NPM % -62.20% -71.35% -55.85% -14.7%
Other Income ₹1 Cr ₹2 Cr ₹2 Cr +185.8%
Depreciation ₹7 Cr ₹6 Cr ₹6 Cr -4.0%
Interest ₹6 Cr ₹7 Cr ₹7 Cr +19.8%
EBIT ₹-22 Cr ₹-12 Cr ₹-9 Cr +45.3%
PBT ₹-27 Cr ₹-17 Cr ₹-14 Cr +37.1%
Tax ₹0 Cr — — —
Net Profit ₹-27 Cr ₹-17 Cr ₹-14 Cr +37.1%
EPS ₹-12.49 ₹-7.86 ₹-6.54 +37.1%
Material Cost ₹3 Cr ₹0 Cr ₹1 Cr -98.0%
Employee Cost ₹17 Cr ₹10 Cr ₹10 Cr -37.4%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 22222222 +0.0%
Reserves -121-141-168-184 -9.5%
Borrowings 183194212225 +6.1%
Other Liabilities 91104103101 -1.9%
Total Liabilities 175178169163 -3.6%
Fixed Assets 147150146142 -2.7%
CWIP 4232 -33.3%
Investments 0000 —
Other Assets 24262020 +0.0%
Total Assets 175178169163 -3.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -252-8-2 +75.0%
Cash from Investing Activity -13-8-5-4 +20.0%
Cash from Financing Activity 376136 -53.8%
Net Cash Flow -000-0 —
Free Cash Flow -36-5-11-5 +54.5%
CFO/OP 157%-27%52%35% -32.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 41400 —
Inventory Days 170543396— —
Days Payable 2171,0511,192— —
Cash Conversion Cycle -44-494-7950 +100.0%
Working Capital Days -232-322-787-1,593 -102.4%
ROCE % -29%-19%-30%-15% +50.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 72.74%72.74%72.74%72.74%72.74% +0.0%
FIIs 0.50%0.50%0.50%0.50%0.50% +0.0%
Public 26.76%26.76%26.76%26.77%26.76% -0.0%
No. of Shareholders 9,1188,9128,7108,5538,533 -0.2%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SMSPHARMA SMS Pharmaceuticals ₹442.45 4,144 39.7 898 102 19.3% 11.4% 13.3% 48.6% 5.6% -1.4%
2 AARTIDRUGS Aarti Drugs ₹428.30 3,909 20.5 2,678 191 12.4% 7.1% 7.5% 16.3% 18.9% -7.2%
3 HIKAL Hikal ₹229.83 2,834 — 1,734 -34 13.4% -2.0% -8.0% -154.4% 6.0% 67.0%
4 BETA Beta Drugs ₹2,064.90 2,084 37.5 513 57 20.5% 11.2% — — 25.5% 31.7%
5 NGLFINE NGL Fine-Chem ₹2,786.60 1,722 30.1 536 57 15.6% 10.6% 36.0% 123.2% 33.6% 99.1%
6 ANUHPHR Anuh Pharma ₹92.99 932 21.1 779 44 8.6% 5.7% 16.5% -12.8% 4.2% 42.8%
7 INFINIUM Infinium Pharma ₹222.95 347 31.2 190 14 11.3% 7.2% — — 45.2% 166.7%
8 AAREYDRUGS Aarey Drugs ₹98.71 329 67.1 415 4 1.6% 1.0% -0.4% 12.3% -56.3% -25.3%
9 PAR Par Drugs ₹128.90 159 10.9 109 14 18.3% 13.3% 2.7% -1.9% 20.1% 41.6%
10 KREBSBIO Krebs Biochemicals ₹57.94 125 — 25 -14 -10.0% -55.9% -45.2% 37.1% 27.4% 53.3%
11 VILINBIO Vilin Bio ₹18.00 27 14.2 42 2 7.6% 4.6% — — 215.9% 1680.0%
❓ Frequently asked questions
What was Krebs Biochemicals and Industries Limited's revenue in Q1 FY27?
Krebs Biochemicals and Industries Limited reported revenue of ₹7 crore for the quarter ended June 2026 (Q1 FY27), up 27.4% from ₹5 crore in the same quarter last year, and up 2.6% sequentially over the March 2026 quarter.
What was Krebs Biochemicals and Industries Limited's net profit in Q1 FY27?
The company reported a net loss of ₹2 crore, against a net loss of ₹5 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-1.15.
What is KREBSBIO's market capitalisation and P/E ratio?
At the current price of ₹60.19, KREBSBIO has a market capitalisation of ₹130 crore.
Who owns Krebs Biochemicals and Industries Limited? (shareholding pattern)
As of Sep 2026, promoters held 72.74%, foreign institutional investors (FIIs) 0.50%, public shareholders 26.76% of Krebs Biochemicals and Industries Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI